Candida peritonitis due to peptic ulcer perforation:: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B

被引:44
作者
Lee, SC [1 ]
Fung, CP
Chen, HY
Li, CT
Jwo, SC
Hung, YB
See, LC
Liao, HC
Loke, SS
Wang, FL
Lee, JC
机构
[1] Chang Gung Mem Hosp, Div Infect Dis, Chilung, Taiwan
[2] Vet Gen Hosp, Div Infect Dis, Taipei, Taiwan
[3] Natl Yang Ming Univ, Taipei 112, Taiwan
[4] Chang Gung Mem Hosp, Dept Surg, Chilung, Taiwan
[5] Chang Gung Univ, Dept Publ Hlth, Linkou, Taiwan
[6] Chang Gung Mem Hosp, Dept Emergency, Chilung, Taiwan
[7] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan 70428, Taiwan
关键词
D O I
10.1016/S0732-8893(02)00419-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Sixty-two cases of peritonitis due to peptic ulcer perforation were diagnosed between January 2000 and December 2000. Of these 62 cases, 23 isolates of Candida in 23 cases (CP) were cultured from peritoneal fluid. Cultures of peritoneal fluid of 10 (BP) of the remaining 39 cases was positive for bacteria only. Cultures of peritoneal fluid of the remaining 29 cases was negative. Comparison of CP, BP and culture-negative cases did not reveal any significant risk factor. Of the 23 Candida isolates, the Candida species and 48-h MICs of fluconazole and amphotericin B (mean, range ug/ml) were C. albicans 18 (0.688, 0.125-1.0; 0.297, 0.031-0.5), C. glabrata 3 (0.542, 0.125-1.0; 0.25, 0.125-0.5), C. tropicalis 1 (0.25; 0.5), C. intermedia 1 (1.0; 0.125) respectively. Mortality rates of CP, BP and culture-negative peritonitis due to infection were 5/23(21.7%), 0/10 and 1/29(3.4%) respectively. Without effective antifungal therapy, the mortality rate of CP was not low. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:23 / 27
页数:5
相关论文
共 20 条
[1]  
Amici G, 1994, Adv Perit Dial, V10, P169
[2]   CANDIDA PERITONITIS - REPORT OF 22 CASES AND REVIEW OF ENGLISH LITERATURE [J].
BAYER, AS ;
BLUMENKRANTZ, MJ ;
MONTGOMERIE, JZ ;
GALPIN, JE ;
COBURN, JW ;
GUZE, LB .
AMERICAN JOURNAL OF MEDICINE, 1976, 61 (06) :832-839
[3]  
BINT AJ, 1987, LANCET, V1, P845
[4]  
CALANDRA T, 1989, LANCET, V2, P1437, DOI 10.1016/S0140-6736(89)92043-6
[5]   Surgical perspective on invasive Candida infections [J].
Dean, DA ;
Burchard, KW .
WORLD JOURNAL OF SURGERY, 1998, 22 (02) :127-134
[6]   Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients [J].
Eggimann, P ;
Francioli, P ;
Bille, J ;
Schneider, R ;
Wu, MM ;
Chapuis, G ;
Chiolero, R ;
Pannatier, A ;
Schilling, J ;
Geroulanos, S ;
Glauser, MP ;
Calandra, T .
CRITICAL CARE MEDICINE, 1999, 27 (06) :1066-1072
[7]   CANDIDA SEPSIS IN SURGICAL PATIENTS [J].
EUBANKS, PJ ;
DEVIRGILIO, C ;
KLEIN, S ;
BONGARD, F .
AMERICAN JOURNAL OF SURGERY, 1993, 166 (06) :617-620
[8]   CANDIDEMIA IN A TERTIARY CARE HOSPITAL - EPIDEMIOLOGY, RISK-FACTORS, AND PREDICTORS OF MORTALITY [J].
FRASER, VJ ;
JONES, M ;
DUNKEL, J ;
STORFER, S ;
MEDOFF, G ;
DUNAGAN, WC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (03) :414-421
[9]  
GILBERT DN, 2001, GUIDE ANTIMICROBIAL, P2
[10]   Cost analysis of Candida infection among surgical intensive care unit patients [J].
Goff, DA ;
Sierawski, SJ ;
Fass, RJ .
CLINICAL DRUG INVESTIGATION, 1996, 12 (04) :176-180